NCT00543920
Completed
Phase 2
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
ConditionsAnxiety Disorders
DrugsMK0777
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Anxiety Disorders
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of General Anxiety Order
Exclusion Criteria
- •Women who are pregnant or breast-feeding
- •History of severe drug reaction
- •History of severe drug withdrawal symptoms such as seizures or delirium
- •Disease of cardiovascular system
- •Disease of the liver, kidneys, endocrine system, metabolic system or eyes
- •History of seizures or seizure disorder
- •History of drug or alcohol abuse
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)Generalized Anxiety DisorderNCT00703833Merck Sharp & Dohme LLC51
Completed
Phase 2
Effect of LY686017 on Alcohol CravingAlcohol DependenceAlcoholismNCT00310427National Institute on Alcohol Abuse and Alcoholism (NIAAA)66
Terminated
Not Applicable
Multimedia Information and Pre-operative AnxietyAnxietyNCT01621828Imperial College London50
Completed
Not Applicable
Treating Young Adult Generalized Anxiety Disorder With Text-Message Delivered Cognitive Behavioral TherapyNCT06774573The University of Tennessee, Knoxville100
Unknown
Not Applicable
Medical Clowns for Pediatric Blood DrawAnxiety StatePainStressNCT03671317University of Southern California60